An observational study in Major Depressive Episode (MDE), Major Depressive Disorder (MDD) and Persistent Depressive Disorder (PDD), sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by The University of Hong Kong · Observational
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders.
To mitigate this issue, the life history calendar (LHC) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the CIDI-5 to measure the lifetime prevalence of mental disorders. The LHC is a grid structure with columns representing time units and rows representing life domains under study.
In a study conducted in Nepal, combining the CIDI-5 with the LHC resulted in a significant increase in the detection of mental disorders compared to using the CIDI-5 alone. This approach did not lead to an increase in false positives after clinical validation.
This experiment aims to adapt a Hong Kong version of the LHC based on the Nepalese model and evaluate the effectiveness of the LHC-assisted CIDI-5 (LHC-CIDI-5) compared to the CIDI-5 alone in assessing mental disorders.
3,041 studies on the registry are indexed under Depressive Disorder, Major; 588 are open to participants now.
This study's planned enrollment of 2,500 is above the median of 131 across 400 observational studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →The University of Hong Kong is the lead sponsor of 1,292 studies on the registry; 348 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study is a sub-study of the District Health Profile (DHP), which is a district-level representative descriptive cross-sectional study. In DHP, 1% of households in selected Hong Kong districts will be randomly selected from the Census and Statistics Department's list of quarters, with stratification based on districts and housing types; all persons aged 18 and above in the recruited households will be included and surveyed. For participants who consent to join the DHP study, a sub-sample of 2,500 participants aged 25 or above will be randomly selected and assigned to two groups through a random process. All 2,500 individuals will complete the survey for the DHP study, including the CIDI-5 section. When administering the CIDI-5, one group of 1,250 individuals will be interviewed using only the CIDI-5, while the other group of 1,250 individuals will be interviewed with LHC first, followed by the CIDI-5.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For the CIDI-5 group, respondents will directly partake in the CIDI-5 interview without responding to any inquiries regarding their life history.
Diagnostic Test: CIDI-5
For the LHC-CIDI-5 group, respondents, before initiating the CIDI-5, will begin with LHC, completing a calendar by answering questions about important personal experiences since birth until the interview year.
Diagnostic Test: LHC-CIDI-5
The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.
The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.
Depression
The main outcomes in this module are the lifetime prevalence of Major Depressive Episode (MDE) and Major Depressive Disorder (MDD)
Time frame: Immediately following intervention or recruitment
Persistent Depression
The main outcome in this module is the lifetime prevalence of Persistent Depressive Disorder (PDD)
Time frame: Immediately following intervention or recruitment
Self Harm
The main outcomes in this module are the lifetime prevalence of Suicidal Ideation, Suicidal Plan, Suicidal Attempt, Suicidal Gesture, and Nonsuicidal Self-Injury.
Time frame: Immediately following intervention or recruitment
High Mood
The main outcomes in this module are the lifetime prevalence of Manic Episode, Hypomanic, Bipolar I Disorder, Bipolar Sub Disorder, and Bipolar II Disorder
Time frame: Immediately following intervention or recruitment
Worry and Anxiety
The main outcome in this module is the lifetime prevalence of Generalized Anxiety Disorder (GAD)
Time frame: Immediately following intervention or recruitment
Anger Attacks
The main outcome in this module is the lifetime prevalence of Intermittent Explosive Disorder (IED)
Time frame: Immediately following intervention or recruitment
Panic Attacks
The main outcomes in this module are the lifetime prevalence of Panic Attack and Panic Disorder.
Time frame: Immediately following intervention or recruitment
Obsessions and Compulsions
The main outcome in this module is the lifetime prevalence of Obsessive-Compulsive Disorder (OCD)
Time frame: Immediately following intervention or recruitment
Stressful Experiences
The main outcomes in this module are the lifetime prevalence of Posttraumatic Stress Disorder (PTSD), PCL-SC PTSD, and PCL-5 PTSD.
Time frame: Immediately following intervention or recruitment
Tobacco, Alcohol, and Drugs
The main outcomes in this module are the lifetime prevalence of Alcohol Use Disorder (AUD) and Substance Use Disorder (SUD)
Time frame: Immediately following intervention or recruitment
Started Jan 2025 (actual). Primary completion is estimated for Sep 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.